Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose

This article was originally published in The Tan Sheet

Executive Summary

FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court
Advertisement

Related Content

Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
DSHEA Implementation Action Expected In Second Session Of 108th Congress
DSHEA Implementation Action Expected In Second Session Of 108th Congress
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
Ephedra Ban Reaction Cautious From Most In Industry; Overdue, Hatch Says
Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman
Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input

Topics

Advertisement
UsernamePublicRestriction

Register

PS096342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel